Navigation Links
Accera, Inc. to Present at the 4th Annual BIO Investor Forum
Date:10/4/2007

BROOMFIELD, Colo., Oct. 4 /PRNewswire/ -- Accera Inc., a privately held biotechnology company focused on developing novel drugs for neurodegenerative diseases, announced today that the company will be participating in the 4th Annual BIO Investor Forum next week at the Palace Hotel in San Francisco:

-- Dr. Lauren Costantini, Vice President of Clinical Development, will

contribute to the panel discussion, "Alzheimer's Disease - Novel

Mechanisms and Targets Renewing the Future of Patients" on Wednesday,

October 10 at 9:10 a.m. PDT.

-- Dr. Steve Orndorff, President and CEO, will present on Thursday,

October 11 at 11:00 a.m. PDT.

Dr. Orndorff will provide an overview of Accera and its technology platform as well as a summary of the positive data from the company's Phase IIb studies of its lead therapeutic product, Ketasyn(TM) (AC-1202) in Alzheimer's disease (AD) and age-associated memory impairment (AAMI). In both studies, Ketasyn was shown to significantly improve memory and cognition using a battery of neuropsychometric tests, including ADAS-Cog, the FDA's gold- standard efficacy measure for AD drugs. Ketasyn was also well tolerated in both indications, even when taken in addition to existing AD drugs, making it a promising candidate for a cotherapeutic approach to treating AD.

About Accera, Inc.

Based in Broomfield, CO, Accera, Inc. is a privately held biotechnology company focused on developing novel drugs for neurodegenerative diseases. The company's lead candidate, Ketasyn(TM) (AC-1202), is a first-in-class molecule that earlier this year completed successful Phase II clinical trials for Alzheimer's disease and age-associated memory impairment (AAMI). A key element of Accera's strategy is to develop AC-1202 and other proprietary small molecule compounds in its pipeline with corporate partners for a range of memory and cognition disorders associated with neurological conditions and aging. http://www.accerapharma.com

About Ketasyn(TM)

Brain imaging techniques performed on Alzheimer's patients reveal a dramatically decreased uptake of glucose, the brain's preferred source of energy. Known as neuronal hypometabolism, this condition resembles diabetes in the brain, or Type III diabetes. Ketasyn(TM) (AC-1202) is an orally available, liquid compound that is efficiently converted into ketone bodies, an alternative energy source that the brain can use even when glucose metabolism is impaired. By preserving glucose-deprived neurons, Ketasyn demonstrates neuroprotective and disease modifying potential in a number other neurodegenerative diseases characterized by neuronal hypometabolism. This first-in-class compound is also being evaluated in age-associated memory impairment, Parkinson's disease, and selected orphan drug indications.

For information contact:

Meghan Feeks

Richard Lewis Communications, Inc.

212-827-0020

mfeeks@rlcinc.com


'/>"/>
SOURCE Accera Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... Cambridge, MA (PRWEB) , ... January 20, 2017 ... ... and scientific consulting and resource to the healthcare industry ( http://www.gandlscientific.com ), has ... to its expanding team of clinical and scientific consultants and contractors. This is ...
(Date:1/21/2017)... , Jan. 20, 2017 Interpace ... a company that provides clinically useful molecular diagnostic ... has entered into a securities purchase agreement with ... 855,000 shares of common stock in a registered ... Company has agreed to sell to the same ...
(Date:1/21/2017)... , Jan. 21, 2017   Boston Biomedical ... compounds designed to target cancer stemness pathways, today presented ... compound, napabucasin, at the 2017 American Society of Clinical ... Francisco . In a Phase ... agent designed to inhibit cancer stemness pathways by targeting ...
(Date:1/20/2017)... 20, 2017 Ginkgo Bioworks, the organism ... pioneer in the synthesis and assembly of DNA. ... assembling pathway-length synthetic DNA into Ginkgo,s automated organism ... the construction of new organism designs for application ... "Gen9 was founded to significantly increase the world,s ...
Breaking Biology Technology:
(Date:1/6/2017)... JOLLA, Calif. , Jan. 6, 2017 /PRNewswire/ ... 1 safety studies in healthy volunteers of a ... intended to treat acute pancreatitis. ... is typically a mild disorder, but can be ... organ failure and sepsis, where extended hospital stays, ...
(Date:1/3/2017)... 3, 2017 Onitor, provider of digital health ... Track, an innovative biometric data-driven program designed to aid ... at the 2017 Consumer Electronics Show (CES) in ... the U.S., the World Health Organization (WHO), have identified ... adults who are overweight or obese. WHO also states ...
(Date:12/19/2016)... TORONTO , 19 de diciembre de 2016  Mosaic ... permitirá el desarrollo acelerado de MSC-1, un anticuerpo humanizado que se ... tumor en 2017, con múltiples sitios previstos a lo largo de ... ... el factor inhibidor de leucemia (LIF), una citoquina pleiotrópica que se ...
Breaking Biology News(10 mins):